Alghamdi Waleed M, Alrasheed Saif H, Nair Vishakh, Alluwimi Muhammed S
Department of Optometry, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.
Clin Ophthalmol. 2021 Mar 1;15:891-898. doi: 10.2147/OPTH.S291991. eCollection 2021.
To assess the effects of 0.5% and 1% cyclopentolate on the main parameters of the anterior segment (central corneal thickness (CCT), anterior chamber angle (ACA), depth (ACD) and volume (ACV)) in low/moderate myopia and hyperopia along with the effect on IOP.
Both eyes of 30 subjects (15 myopic and 15 hyperopic) with mean age±standard deviation of 21.4±3.6 years were enrolled. Each participant was administered two drops of cyclopentolate 1% in the right eye and two drops of cyclopentolate 0.5% in the left eye, 15 minutes apart. All participants underwent intraocular pressure (IOP) measurement using noncontact tonometry, and anterior chamber parameter measurement using Pentacam.
Following the use of 0.5% and 1% cyclopentolate among the hyperopic group, there was a statistically significant increase in ACD for 1% (pre 2.762±0.28 mm and post 2.89±0.25 mm) and 0.5% (pre 2.71±0.28 and post 2.86±0.27 mm) and ACV for 1% (pre 141.40±20.59 mm and post 154.35±19.69 mm) and 0.5% (pre 137.40±20.48 mm and post 152.93±20.50 mm). In contrast, ACA decreased with both doses 1% and 0.5%, but was not statistically significant ( for both >0.05%). With 0.5% and 1% cyclopentolate among the myopia group, there was a significant increase in ACD following cyclopentolate 1% (pre 3.18±0.22 mm and post 3.25±0.21 mm) and 0.5% (pre 3.200±0.22 mm and post 3.26±0.05 mm), ˂0.05. The ACV was significantly increased following 1% cyclopentolate, ˂0.001. The ACA showed a statistically significant decrease following cyclopentolate 1%, =0.01, but not a significant decrease after cyclopentolate 0.5%, =0.170. There was a significant increase in the IOP after 1%, ˂0.001, while a decrease with 0.5%, =0.008.
A topical dosage of cyclopentolate 1% showed significant changes in ACA and ACV among the hyperopia and myopic groups compared to 0.5%. Therefore, it is important to consider the use of a 0.5% cyclopentolate dosage to minimize changes to anterior chamber parameters.
评估0.5%和1%的环喷托酯对低度/中度近视和远视患者眼前节主要参数（中央角膜厚度（CCT）、前房角（ACA）、深度（ACD）和容积（ACV））的影响以及对眼压（IOP）的影响。
纳入30名受试者（15名近视和15名远视），平均年龄±标准差为21.4±3.6岁。每位参与者右眼滴入两滴1%的环喷托酯，左眼滴入两滴0.5%的环喷托酯，间隔15分钟。所有参与者使用非接触眼压计测量眼压，并使用Pentacam测量前房参数。
在远视组中使用0.5%和1%的环喷托酯后，1%组（用药前2.762±0.28mm，用药后2.89±0.25mm）和0.5%组（用药前2.71±0.28，用药后2.86±0.27mm）的ACD有统计学显著增加，1%组（用药前141.40±20.59mm，用药后154.35±19.69mm）和0.5%组（用药前137.40±20.48mm，用药后152.93±20.50mm）的ACV有统计学显著增加。相比之下，1%和0.5%剂量的环喷托酯均使ACA降低，但无统计学显著性（两者均>0.05%）。在近视组中使用0.5%和1%的环喷托酯后，1%组（用药前3.18±0.22mm，用药后3.25±0.21mm）和0.5%组（用药前3.200±0.22mm，用药后3.26±0.05mm）的ACD有显著增加，P<0.05。1%的环喷托酯使ACV显著增加，P<0.001。1%的环喷托酯使ACA有统计学显著降低，P = 0.01，但0.5%的环喷托酯后ACA无显著降低，P = 0.170。1%的环喷托酯使眼压显著升高，P<0.001，而0.5%的环喷托酯使眼压降低，P = 0.008。
与0.5%的环喷托酯相比，1%的环喷托酯局部用药在远视和近视组的ACA和ACV方面显示出显著变化。因此，考虑使用0.5%的环喷托酯剂量以尽量减少对前房参数的改变很重要。
